Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 14-Nov-24 6:01 PM View:  | Halstead Michael President | Intra-Cellular Therapies, I... (ITCI) | 13-Nov-24 | Planned Option Sale | 18,714 | $88.38 | $1,654,020.00 | (100%) 18.71K to 0 | |
| 14-Nov-24 6:01 PM View: | Halstead Michael President | Intra-Cellular Therapies, I... (ITCI) | 13-Nov-24 | Option Exercise | 18,714 | $36.89 | $690,359.00 | 100% 0 to 18.71K | |
| 14-Nov-24 6:01 PM View: | Halstead Michael President | Intra-Cellular Therapies, I... (ITCI) | 12-Nov-24 | Option Exercise | 22,869 | $23.94 | $547,484.00 | 100% 0 to 22.87K | |
| 14-Nov-24 6:01 PM View: | Halstead Michael President | Intra-Cellular Therapies, I... (ITCI) | 12-Nov-24 | Planned Option Sale | 22,869 | $89.12 | $2,038,080.00 | (100%) 22.87K to 0 | |
| 30-Aug-24 6:01 PM View: | Mates Sharon Chairman and CEO Director | Intra-Cellular Therapies, I... (ITCI) | 30-Aug-24 | Option Exercise | 34,396 | $12.73 | $437,861.00 | 3% 1.07M to 1.1M | |
| 30-Aug-24 6:01 PM View: | Mates Sharon Chairman and CEO Director | Intra-Cellular Therapies, I... (ITCI) | 30-Aug-24 | Planned Option Sale | 34,396 | $72.84 | $2,505,350.00 | (3%) 1.1M to 1.07M | |
| 30-Aug-24 6:01 PM View: | Mates Sharon Chairman and CEO Director | Intra-Cellular Therapies, I... (ITCI) | 29-Aug-24 | Planned Option Sale | 35,604 | $72.57 | $2,583,880.00 | (3%) 1.11M to 1.07M | |
| 30-Aug-24 6:01 PM View: | Mates Sharon Chairman and CEO Director | Intra-Cellular Therapies, I... (ITCI) | 29-Aug-24 | Option Exercise | 35,604 | $12.73 | $453,239.00 | 3% 1.07M to 1.11M | |
| 28-Aug-24 6:00 PM View: | Mates Sharon Chairman and CEO Director | Intra-Cellular Therapies, I... (ITCI) | 28-Aug-24 | Planned Option Sale | 32,699 | $72.75 | $2,378,800.00 | (3%) 1.1M to 1.07M | |
| 28-Aug-24 6:00 PM View: | Mates Sharon Chairman and CEO Director | Intra-Cellular Therapies, I... (ITCI) | 28-Aug-24 | Option Exercise | 32,699 | $17.57 | $574,521.00 | 3% 1.07M to 1.1M | |
| 28-Aug-24 6:00 PM View: | Mates Sharon Chairman and CEO Director | Intra-Cellular Therapies, I... (ITCI) | 27-Aug-24 | Option Exercise | 40,513 | $17.57 | $711,813.00 | 4% 1.07M to 1.11M | |
| 28-Aug-24 6:00 PM View: | Mates Sharon Chairman and CEO Director | Intra-Cellular Therapies, I... (ITCI) | 27-Aug-24 | Planned Option Sale | 40,513 | $73.58 | $2,981,060.00 | (4%) 1.11M to 1.07M | |
| 28-Aug-24 6:00 PM View: | Mates Sharon Chairman and CEO Director | Intra-Cellular Therapies, I... (ITCI) | 26-Aug-24 | Planned Option Sale | 22,713 | $74.59 | $1,694,230.00 | (2%) 1.09M to 1.07M | |
| 28-Aug-24 6:00 PM View: | Mates Sharon Chairman and CEO Director | Intra-Cellular Therapies, I... (ITCI) | 26-Aug-24 | Option Exercise | 22,713 | $17.57 | $399,067.00 | 2% 1.07M to 1.09M | |
| 23-Aug-24 6:00 PM View: | Mates Sharon Chairman and CEO Director | Intra-Cellular Therapies, I... (ITCI) | 23-Aug-24 | Planned Option Sale | 28,680 | $74.46 | $2,135,440.00 | (3%) 1.1M to 1.07M | |
| 23-Aug-24 6:00 PM View: | Mates Sharon Chairman and CEO Director | Intra-Cellular Therapies, I... (ITCI) | 23-Aug-24 | Option Exercise | 28,680 | $17.57 | $503,908.00 | 3% 1.07M to 1.1M | |
| 23-Aug-24 6:00 PM View: | Mates Sharon Chairman and CEO Director | Intra-Cellular Therapies, I... (ITCI) | 22-Aug-24 | Option Exercise | 39,380 | $17.57 | $691,907.00 | 4% 1.07M to 1.11M | |
| 23-Aug-24 6:00 PM View: | Mates Sharon Chairman and CEO Director | Intra-Cellular Therapies, I... (ITCI) | 22-Aug-24 | Planned Option Sale | 39,380 | $74.68 | $2,940,800.00 | (4%) 1.11M to 1.07M | |
| 23-Aug-24 6:00 PM View: | Mates Sharon Chairman and CEO Director | Intra-Cellular Therapies, I... (ITCI) | 21-Aug-24 | Planned Option Sale | 53,013 | $75.65 | $4,010,500.00 | (5%) 1.12M to 1.07M | |
| 23-Aug-24 6:00 PM View: | Mates Sharon Chairman and CEO Director | Intra-Cellular Therapies, I... (ITCI) | 21-Aug-24 | Option Exercise | 53,013 | $17.57 | $931,438.00 | 5% 1.07M to 1.12M | |
| 20-Aug-24 6:03 PM View: | Neumann Mark EVP, Chief Commercial Officer | Intra-Cellular Therapies, I... (ITCI) | 16-Aug-24 | Option Sale | 18,714 | $75.08 | $1,405,050.00 | (39%) 48.41K to 29.7K | |
| 20-Aug-24 6:03 PM View: | Neumann Mark EVP, Chief Commercial Officer | Intra-Cellular Therapies, I... (ITCI) | 16-Aug-24 | Option Exercise | 18,714 | $36.89 | $690,359.00 | 63% 29.7K to 48.41K | |
| 02-Jul-24 8:00 PM View: | Riggs Rory B Director | Intra-Cellular Therapies, I... (ITCI) | 28-Jun-24 | Grant | 262 | $68.49 | $17,944.40 | < 1% 116.6K to 116.86K | |
| 02-Jul-24 8:00 PM View: | van Nostrand Robert L Director | Intra-Cellular Therapies, I... (ITCI) | 28-Jun-24 | Grant | 83 | $68.49 | $5,684.67 | < 1% 11.26K to 11.34K | |
| 25-Jun-24 6:04 PM View: | Riggs Rory B Director | Intra-Cellular Therapies, I... (ITCI) | 24-Jun-24 | Option Exercise | 20,000 | $16.86 | $337,200.00 | 20% 101.06K to 121.06K | |
| 25-Jun-24 6:04 PM View: | Riggs Rory B Director | Intra-Cellular Therapies, I... (ITCI) | 24-Jun-24 | Option Sale | 4,462 | $75.57 | $337,193.00 | (4%) 121.06K to 116.6K | |
| 25-Jun-24 6:05 PM View: | Salas Eduardo Rene Director | Intra-Cellular Therapies, I... (ITCI) | 23-Jun-24 | Option Exercise | 1,567 | -- | -- | 100% 0 to 1.57K | |
| 25-Jun-24 6:05 PM View: | van Nostrand Robert L Director | Intra-Cellular Therapies, I... (ITCI) | 23-Jun-24 | Option Exercise | 1,567 | -- | -- | 16% 9.69K to 11.26K | |
| 25-Jun-24 6:05 PM View: | Marcus Joel S Director | Intra-Cellular Therapies, I... (ITCI) | 23-Jun-24 | Option Exercise | 1,567 | -- | -- | 3% 49.66K to 51.23K | |
| 25-Jun-24 6:04 PM View: | Riggs Rory B Director | Intra-Cellular Therapies, I... (ITCI) | 23-Jun-24 | Option Exercise | 1,567 | -- | -- | 2% 99.5K to 101.06K | |
| 21-Jun-24 6:00 PM View: | van Nostrand Robert L Director | Intra-Cellular Therapies, I... (ITCI) | 18-Jun-24 | Option Exercise | 20,000 | $16.86 | $337,200.00 | 206% 9.69K to 29.69K | |
| 21-Jun-24 6:00 PM View: | van Nostrand Robert L Director | Intra-Cellular Therapies, I... (ITCI) | 18-Jun-24 | Planned Option Sale | 20,000 | $75.91 | $1,518,200.00 | (67%) 29.69K to 9.69K | |
| 25-Apr-24 5:08 PM View: | Mates Sharon Chairman and CEO Director | Intra-Cellular Therapies, I... (ITCI) | 24-Apr-24 | Option Exercise | 20,020 | $17.26 | $345,618.00 | 2% 1.05M to 1.07M | |
| 02-Apr-24 4:15 PM View: | Riggs Rory B Director | Intra-Cellular Therapies, I... (ITCI) | 31-Mar-24 | Grant | 260 | $69.20 | $17,992.00 | < 1% 99.23K to 99.5K | |
| 02-Apr-24 4:15 PM View: | van Nostrand Robert L Director | Intra-Cellular Therapies, I... (ITCI) | 31-Mar-24 | Grant | 79 | $69.20 | $5,466.80 | < 1% 9.61K to 9.69K | |
| 22-Mar-24 4:12 PM View: | Riggs Rory B Director | Intra-Cellular Therapies, I... (ITCI) | 20-Mar-24 | Option Exercise | 20,000 | $18.56 | $371,200.00 | 25% 79.23K to 99.23K | |
| 11-Mar-24 8:33 PM View: | Mates Sharon Chairman, President & CEO Director | Intra-Cellular Therapies, I... (ITCI) | 11-Mar-24 | Sale (Planned) | 20,565 | $65.21 | $1,341,120.00 | (2%) 1.07M to 1.05M | |
| 11-Mar-24 8:33 PM View: | Hineline Lawrence J. SVP of Finance, CFO | Intra-Cellular Therapies, I... (ITCI) | 11-Mar-24 | Sale (Planned) | 5,582 | $65.96 | $368,192.00 | (100%) 5.58K to 0 | |
| 11-Mar-24 8:31 PM View: | Durgam Suresh K. EVP, Chief Medical Officer | Intra-Cellular Therapies, I... (ITCI) | 11-Mar-24 | Planned Option Sale | 895 | $65.59 | $58,706.00 | (4%) 23.52K to 22.62K | |
| 11-Mar-24 8:31 PM View: | Neumann Mark EVP, Chief Commercial Officer | Intra-Cellular Therapies, I... (ITCI) | 11-Mar-24 | Sale (Planned) | 7,345 | $65.61 | $481,931.00 | (20%) 37.05K to 29.7K | |
| 11-Mar-24 8:32 PM View: | Halstead Michael EVP and General Counsel | Intra-Cellular Therapies, I... (ITCI) | 11-Mar-24 | Sale (Planned) | 7,345 | $65.97 | $484,537.00 | (100%) 7.34K to 0 | |
| 11-Mar-24 8:31 PM View: | Durgam Suresh K. EVP, Chief Medical Officer | Intra-Cellular Therapies, I... (ITCI) | 11-Mar-24 | Sale (Planned) | 2,817 | $65.59 | $184,776.00 | (12%) 22.62K to 19.8K | |
| 11-Mar-24 8:33 PM View: | Hineline Lawrence J. SVP of Finance, CFO | Intra-Cellular Therapies, I... (ITCI) | 11-Mar-24 | Planned Option Sale | 4,539 | $65.96 | $299,395.00 | (45%) 10.12K to 5.58K | |
| 11-Mar-24 8:31 PM View: | Durgam Suresh K. EVP, Chief Medical Officer | Intra-Cellular Therapies, I... (ITCI) | 10-Mar-24 | Option Exercise | 7,345 | -- | -- | 45% 16.17K to 23.52K | |
| 11-Mar-24 8:33 PM View: | Mates Sharon Chairman, President & CEO Director | Intra-Cellular Therapies, I... (ITCI) | 10-Mar-24 | Option Exercise | 20,565 | -- | -- | 2% 1.05M to 1.07M | |
| 11-Mar-24 8:32 PM View: | Halstead Michael EVP and General Counsel | Intra-Cellular Therapies, I... (ITCI) | 10-Mar-24 | Option Exercise | 7,345 | -- | -- | 100% 0 to 7.34K | |
| 11-Mar-24 8:31 PM View: | Neumann Mark EVP, Chief Commercial Officer | Intra-Cellular Therapies, I... (ITCI) | 10-Mar-24 | Option Exercise | 7,345 | -- | -- | 25% 29.7K to 37.05K | |
| 11-Mar-24 8:33 PM View: | Hineline Lawrence J. SVP of Finance, CFO | Intra-Cellular Therapies, I... (ITCI) | 07-Mar-24 | Planned Private Option Sale | 5,582 | $66.60 | $371,748.00 | (43%) 13.13K to 7.55K | |
| 11-Mar-24 8:31 PM View: | Neumann Mark EVP, Chief Commercial Officer | Intra-Cellular Therapies, I... (ITCI) | 07-Mar-24 | Sale (Planned) | 5,787 | $66.57 | $385,232.00 | (16%) 35.49K to 29.7K | |
| 11-Mar-24 8:32 PM View: | Halstead Michael EVP and General Counsel | Intra-Cellular Therapies, I... (ITCI) | 07-Mar-24 | Sale (Planned) | 5,787 | $66.15 | $382,817.00 | (100%) 5.79K to 0 |
